The FDA is transitioning back to traditional regulatory processes to sign off on new COVID-19 tests after clearing more than 430 for emergency use during the pandemic, the agency said Sept. 27.
A Department of Health and Human Services report found single-use medical devices account for most of hospital greenhouse gas emissions and lead to supply chain disruptions.
After some pharmacies and hospitals reported running out of Moderna’s omicron-targeted booster, the FDA authorized five lots of the product made at the drugmaker’s Bloomington, Ind., facility, which isn’t authorized to manufacture the modified vaccine….
With COVID-19 vaccine-makers pivoting production as the virus mutates, Jim Cafone, Pfizer’s senior vice president of global supply chain, said it is time for pharmaceutical companies to redevelop their logistic strategies, The Wall Street Journal repor…
Reauthorizing the FDA’s user fee program, which allows the agency to decide how much to charge pharmaceutical and medical device-maker companies for their product submissions, was added to a spending bill Sept. 22 to prevent a government shutdown…
From an unusual number of submissions of low-quality COVID-19 tests to limits at U.S. laboratories, the FDA faced multiple barriers in the early days of the COVID-19 pandemic, an HHS report found.
For many ASCs, including Wilmington (N.C.) Surgcare, staffing and supply chain issues have plagued operations since the beginning of the COVID-19 pandemic.
Drug and medical devicemakers with operations in Puerto Rico are cautiously optimistic that Hurricane Fiona will cause few ripples across the medical supply chain.